FI3188727T3 - Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi - Google Patents

Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi Download PDF

Info

Publication number
FI3188727T3
FI3188727T3 FIEP15766274.3T FI15766274T FI3188727T3 FI 3188727 T3 FI3188727 T3 FI 3188727T3 FI 15766274 T FI15766274 T FI 15766274T FI 3188727 T3 FI3188727 T3 FI 3188727T3
Authority
FI
Finland
Prior art keywords
tasimelteon
use according
sleep
improvement
day
Prior art date
Application number
FIEP15766274.3T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Christian Lavedan
Mihael Polymeropoulos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3188727(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of FI3188727T3 publication Critical patent/FI3188727T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Processing Of Solid Wastes (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Led Device Packages (AREA)
  • Saccharide Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Indole Compounds (AREA)
FIEP15766274.3T 2014-09-02 2015-08-29 Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi FI3188727T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US201562169635P 2015-06-02 2015-06-02
PCT/US2015/047610 WO2016036619A1 (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Publications (1)

Publication Number Publication Date
FI3188727T3 true FI3188727T3 (fi) 2023-02-20

Family

ID=54147267

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15766274.3T FI3188727T3 (fi) 2014-09-02 2015-08-29 Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi

Country Status (17)

Country Link
US (5) US10179119B2 (enExample)
EP (2) EP3188727B1 (enExample)
JP (3) JP6903571B2 (enExample)
KR (2) KR20170048541A (enExample)
CN (2) CN106604726A (enExample)
AU (2) AU2015312252B2 (enExample)
BR (1) BR112017003644A2 (enExample)
CA (2) CA3124872A1 (enExample)
DK (1) DK3188727T3 (enExample)
ES (1) ES2936833T3 (enExample)
FI (1) FI3188727T3 (enExample)
HR (1) HRP20230070T1 (enExample)
HU (1) HUE061051T2 (enExample)
MX (1) MX386150B (enExample)
PT (1) PT3188727T (enExample)
SI (1) SI3188727T1 (enExample)
WO (1) WO2016036619A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CN106604726A (zh) * 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
EP3761974A1 (en) * 2018-03-04 2021-01-13 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
JP2022500420A (ja) * 2018-09-12 2022-01-04 バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. 睡眠又は睡眠後パフォーマンスの改善
NZ811397A (en) 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof
US20230314471A1 (en) 2020-08-27 2023-10-05 Yokowo Co., Ltd. Inspection device
AU2022345260A1 (en) * 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
IL330095A (en) * 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备(1r,2r)-2-(2,3-二氢苯并呋喃-4-基)环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Also Published As

Publication number Publication date
JP7252390B2 (ja) 2023-04-04
US20190105297A1 (en) 2019-04-11
EP4137129A1 (en) 2023-02-22
KR20170048541A (ko) 2017-05-08
ES2936833T3 (es) 2023-03-22
EP3188727B1 (en) 2022-11-09
US20170239210A1 (en) 2017-08-24
JP2022078291A (ja) 2022-05-24
SI3188727T1 (sl) 2023-03-31
NZ729901A (en) 2020-09-25
CN116098887A (zh) 2023-05-12
JP6903571B2 (ja) 2021-07-14
AU2020239640A1 (en) 2020-10-15
US20240293355A1 (en) 2024-09-05
JP2017526693A (ja) 2017-09-14
DK3188727T3 (da) 2023-02-06
US20200237712A1 (en) 2020-07-30
CA2957588A1 (en) 2016-03-10
US20220133681A1 (en) 2022-05-05
US10653665B2 (en) 2020-05-19
AU2015312252B2 (en) 2020-07-02
CA3124872A1 (en) 2016-03-10
KR20240015729A (ko) 2024-02-05
WO2016036619A1 (en) 2016-03-10
HUE061051T2 (hu) 2023-05-28
CN106604726A (zh) 2017-04-26
MX386150B (es) 2025-03-18
AU2020239640B2 (en) 2020-11-05
JP7132277B2 (ja) 2022-09-06
CA2957588C (en) 2021-08-31
BR112017003644A2 (pt) 2017-11-28
PT3188727T (pt) 2023-01-30
US10179119B2 (en) 2019-01-15
NZ765911A (en) 2023-08-25
HRP20230070T1 (hr) 2023-03-17
JP2020143159A (ja) 2020-09-10
US11266622B2 (en) 2022-03-08
MX2017002796A (es) 2017-06-09
AU2015312252A1 (en) 2017-03-30
EP3188727A1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
RU2015129349A (ru) Лечение расстройств циркадного ритма
HRP20230070T1 (hr) Tasimelteon za liječenje smith-magenis sindroma
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
RU2014134555A (ru) Лечение нарушений циркадного ритма
EA202090043A1 (ru) Диазабициклические замещенные имидазопиримидины и их применение
JP2017526693A5 (enExample)
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
HRP20201069T1 (hr) Primjena tasimelteona pod uvjetima natašte
JP2016014009A5 (enExample)
ATE506941T1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
FI3298042T3 (fi) B-solujen vähentyminen diagnostisena merkkinä
BR112016029749A2 (pt) composições que compreendem cinamaldeído e zinco e métodos de uso de tais composições
Tepper Sleep disorders and headache.
RU2022101535A (ru) Лемборексант для лечения проблем со сном
LI et al. Clinical Short-term Effects of Nd: YAG Laser and CO2 Laser on Minor Aphthous Ulcer
CN105560290A (zh) 用于治疗小儿夜啼的蝉金散
Arasalingam Sleep disorders in Parkinson disease
RU2015109209A (ru) Способ количественной оценки зубочелюстно-лицевых аномалий
UA89580U (ru) Способ комплексной психофармакотерапии аффективных расстройств у больных вич/спид
Pasha Various toxicities: 3 case reports
RU2012115056A (ru) Способ лечения пациентов с избыточной массой тела и нарушениями сна
CN105617206A (zh) 治疗口臭的中药
UA85304U (ru) Способ комплексной терапии первого эпизода шизофрении с непрерывным течением и агрессивным поведением
CN104587357A (zh) 一种治疗口臭的中药